Tag: <span>high-risk patient</span>

Home / high-risk patient
A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population
Post

A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population

by  The Mount Sinai Hospital The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored...